| Japanese |
|---|
| Title | 99mTc標識Bleomycinによる腫瘍シンチグラフィに関する研究 - 第1編 標識法の基礎的検討および臨床利用に関する研究 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 小鳥輝男* |
|---|
| Authors(kana) | |
|---|
| Organization | *京都大学医学部附属病院放射線部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 16 |
|---|
| Number | 5 |
|---|
| Page | 721-733 |
|---|
| Year/Month | 1979/8 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」99mTc-Bleomycinの標識条件の基礎的検討およびそのキット標識の検討を行ない, Sn-resinを用いることにより極少量の錫量でも還元力の低下をきたさず, アスコルビン酸を必要としないで安定な99mTc-BCMを製成し得るキット標識法を考察した. またこのキット標識による99mTC-BLMを用いて各種悪性, 良性疾患におけるシンチグラフィを用い, あわせて67Gaシンチグラフィを行なって, 両者の成績の比較検討を行なった. 99mTd-BLMによるsensitivity, specificityはそれぞれ73%, 72%であり, 67Gaによる64%, 41%に比し優れる成績を示した. 99mTc-BLMは静注投与30分〜1時間後のなおバックグラウンドの高い時期に撮像するため, 体幹部において67Gaに比し劣る成績であったが, 四肢, 頭頸部においては非常に優れた成績を示した. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-labeled bleomycin, Kit method and labeling analysis, 67Ga citrate, Tumor seeking scintigraphic agents |
|---|
| English |
|---|
| Title | Clinical Evaluation of Tumor Scintigraphy with 99mTc-Bleomycin (Part I) Fundamental Studies on Labelling Methods of 99mTc-Bleomycin and Its Clinical Application |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Teruo ODORI |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Radiology and Nuclear Medicine, Kyoto University Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 16 |
|---|
| Number | 5 |
|---|
| Page | 721-733 |
|---|
| Year/Month | 1979/8 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Fundamental studies on the labeling techniques for 99mTc-Bleomycin (99mTc-BLM) were performed. Among them, Sn-resin kit method was found to be the best method, which could produce the most chemically stable 99mTc-BLM, requiring minimum amount of tin without ascorbic acid. Clinical evaluation of the kit labeled 99mTc-BLM was performed in various malignant and benign diseases. A comparative study with 67Ga citrate (67Ga) scintigraphy was also performed. 99mTc-BLM was revealed to have superior sensitivity and specificity of 73% and 72% for malignant tumors over those with 67Ga of 64% and 41%, respectively. Though 99mTc-BLM scintigraphy had a disadvantage in detecting lesions in the trunk comparing to 67Ga scintigraphy due to the high back ground radioactivity from 30 min. to 1 hr. after intravenous injection, it provides a excellent means in detecting malignant tumors in the limbs, head and neck. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-labeled bleomycin, Kit method and labeling analysis, 67Ga citrate, Tumor seeking scintigraphic agents |
|---|